Lipocomb (Ezetimibe, Rosuvastatin Zinc)

Ezetimibe, one component of Lipocomb, inhibits the NPC1L1 transporter on intestinal cells, which blocks the absorption of dietary and biliary cholesterol. This reduction in intestinal cholesterol uptake complements rosuvastatin’s inhibition of hepatic cholesterol synthesis, leading to greater LDL‑cholesterol lowering.

The specific dose of Lipocomb is determined by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk, and tolerability. Healthcare professionals select the appropriate strength and dosing schedule according to current clinical guidelines.

Lipocomb is contraindicated in pregnancy because both ezetimibe and rosuvastatin may cause fetal harm. It is also not recommended while breastfeeding, as the drugs can pass into breast milk and affect the infant. Women of child‑bearing potential should use effective contraception.

To request Lipocomb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Statin‑only therapy lowers cholesterol by reducing hepatic synthesis, while Lipocomb adds ezetimibe, which blocks intestinal absorption. This dual mechanism often achieves greater LDL‑cholesterol reduction than a statin alone, especially in patients who need additional lipid control or who have statin intolerance at higher doses.

Lipocomb tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Lipocomb is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

The most serious risks include rhabdomyolysis (severe muscle breakdown), acute liver injury, and severe allergic reactions such as anaphylaxis. Patients should promptly report unexplained muscle pain, dark urine, jaundice, or signs of hypersensitivity to their healthcare provider.

Lipocomb should not be used by individuals who are pregnant, breastfeeding, or have known hypersensitivity to ezetimibe, rosuvastatin, or any excipients. It is also contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic enzymes.